Bayer AG (NASDAQ:BAYRY) Receives Consensus Recommendation of “Buy” from Brokerages
Bayer AG (NASDAQ:BAYRY) has been given a consensus rating of “Buy” by the eight ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company.
A number of equities analysts have weighed in on BAYRY shares. Zacks Investment Research lowered Bayer AG from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Berenberg Bank lowered Bayer AG from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd.
Shares of Bayer AG (NASDAQ:BAYRY) opened at 125.67 on Tuesday. Bayer AG has a one year low of $91.53 and a one year high of $139.04. The company has a market cap of $109.60 billion and a PE ratio of 18.69.
Bayer AG (NASDAQ:BAYRY) last announced its quarterly earnings results on Thursday, July 27th. The company reported $1.99 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.12. The company had revenue of $13.41 billion for the quarter, compared to analysts’ expectations of $14.45 billion. Bayer AG had a net margin of 16.40% and a return on equity of 24.89%. On average, equities analysts predict that Bayer AG will post $9.09 EPS for the current year.
Bayer AG Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.